Share-based Payment Arrangement, Expense of Finch Therapeutics Group, Inc. from 31 Mar 2020 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Finch Therapeutics Group, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Jun 2024.
  • Finch Therapeutics Group, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2024 was $15,000, a 95% decline year-over-year.
  • Finch Therapeutics Group, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2024 was $492,000, a 91% decline year-over-year.
  • Finch Therapeutics Group, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,929,000, a 75% decline from 2022.
  • Finch Therapeutics Group, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,844,000, a 89% increase from 2021.
  • Finch Therapeutics Group, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4,161,000, a 34% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Finch Therapeutics Group, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $492,000 $15,000 -$285,000 -95% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $777,000 $28,000 -$1,152,000 -98% 01 Jan 2024 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $1,929,000 $114,000 -$1,679,000 -94% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2024 2023 FY
Q3 2023 $3,608,000 $335,000 -$1,766,000 -84% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $5,374,000 $300,000 -$1,530,000 -84% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $6,904,000 $1,180,000 -$940,000 -44% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $7,844,000 $1,793,000 +$387,000 +28% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $7,457,000 $2,101,000 +$586,000 +39% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $6,871,000 $1,830,000 +$925,000 +102% 01 Apr 2022 30 Jun 2022 10-Q/A 11 Aug 2023 2023 Q2
Q1 2022 $5,946,000 $2,120,000 +$1,785,000 +533% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $4,161,000 $1,406,000 -$1,471,000 -51% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $5,632,000 $1,515,000 +$1,459,000 +2605% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $4,173,000 $905,000 +$817,000 +928% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,356,000 $335,000 +$257,000 +329% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $3,099,000 $2,877,000 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $56,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $88,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $78,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

Finch Therapeutics Group, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $1,929,000 -$5,915,000 -75% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2024 2023 FY
2022 $7,844,000 +$3,683,000 +89% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $4,161,000 +$1,062,000 +34% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $3,099,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.